On January 26, 2021, Split Biosciences, a company providing researchers scalable and flexible single-cell sequencing solutions, announced $7M in Series A funding. The funding round was led by Bioeconomy Capital, an early-stage VC firm specializing in companies developing life science tools, with participation from new and existing angel investors. Split Bio also announced a rebrand of the company to Parse Biosciences (http://www.parsebiosciences.com/). The new funding will be used to continue scaling the commercial roll-out of Parse Bioscience’s Whole Transcriptome Kit, which enables researchers to profile up to 100,000 cells in parallel across up to 48 samples. In addition to increased scalability, Parse Biosciences’s technology also provides researchers with higher data quality. Parse enables researchers to increase gene detection in individual cells, while dramatically reducing confounding artifacts that are common in single-cell sequencing experiments. The new brand comes as Parse Biosciences matures beyond the initial academic research upon which the company was founded and in the wake of significant advancements in its technology. “We have spent the last three years developing a product that more scientists could actually use,” said Charlie Roco, PhD, Co-Founder and CTO of Parse Biosciences. “Our kits are now operating at a higher level than anything else we’ve seen on the market and our company has evolved beyond our original SPLiT-seq method. We wanted our brand to reflect that.” Researchers in both the pharmaceutical industry and academia have increasingly leveraged single-cell technologies to drive discovery.
Login Or Register To Read Full Story